Presentation will Showcase Demo Style and design in Upcoming Stage 3 Trial in Parkinson’s Sickness
Berwyn, Pennsylvania–(Newsfile Corp. – March 8, 2022) – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-phase drug system company addressing neurodegenerative health conditions, these days introduced that the Organization will be presenting at the International Conference on Alzheimer’s & Parkinson’s Conditions (Advertisement/PD™ 2022). The hybrid convention will be hosted in-individual in Barcelona, Spain, and just about from March 15-20, 2022.
Maria L. Maccecchini, Ph.D., Founder, President, and CEO, and Cheng Fang, Ph.D., Senior Vice President of Investigation & Improvement, will participate in-man or woman.
The presentation will showcase endpoints and demo style of the Firm’s upcoming Section 3 scientific experiments of Buntanetap (formerly identified as Posiphen or ANVS401) for the procedure of Parkinson’s Sickness (PD).
Title: Constructive clinical results of Posiphen in two Section 2a studies – Alzheimer’s Illness and Parkinson’s Illness
Summary: SO394 / #308
Session: ABeta and other focusing on therapies in Advertisement
Time: March 20, from 9:05-11:05 a.m. C.E.T. / 3:05-5:05 a.m. E.T.
Presenter: Maria L. Maccecchini, Ph.D., Founder, CEO and President, Annovis Bio
About Annovis Bio, Inc.
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a medical-stage, drug system business addressing neurodegeneration, these types of as Alzheimer’s condition (Ad), Parkinson’s illness (PD), and other persistent neurodegenerative diseases, such as Alzheimer’s in Down Syndrome (Ad-DS). We think that we are the only corporation building a drug for Advertisement, PD, and Advert-DS that inhibits extra than just one neurotoxic protein and, therefore, enhances the data freeway of the nerve mobile, recognised as axonal transport. When this information and facts movement is impaired, the nerve cell will get unwell and dies. Annovis performed two Section 2 experiments: a person in Ad people and one in both of those Ad and PD people. In the Advertisement/PD analyze Buntanetap showed enhancement in memory reduction and dementia related with Ad, as perfectly as system and mind purpose in PD.
Statements in this push release contain “forward-wanting statements” that are issue to significant risks and uncertainties. Forward-searching statements contained in this press launch may perhaps be discovered by the use of terms these types of as “foresee,” “anticipate,” “imagine,” “will,” “may possibly,” “should really,” “estimate,” “task,” “outlook,” “forecast” or other related terms, and involve, without limitation, statements about the timing, effectiveness, and predicted success of Buntanetap medical trials. Ahead-searching statements are primarily based on Annovis Bio, Inc.’s existing anticipations and are matter to inherent uncertainties, pitfalls and assumptions that are complicated to predict. Even more, specified forward-searching statements are based mostly on assumptions as to long run functions that might not demonstrate to be correct. These and other challenges and uncertainties are described far more absolutely in the part titled “Hazard Elements” in the Yearly Report on Variety 10-K for the 12 months ended December 31, 2021, submitted with the Securities and Trade Commission. Ahead-seeking statements contained in this announcement are designed as of this day, and Annovis Bio, Inc. undertakes no responsibility to update these kinds of info apart from as needed under relevant legislation.
Media and Trader Make contact with:
Russo Associates, LLC
To see the resource edition of this press release, be sure to pay a visit to https://www.newsfilecorp.com/launch/115916